ARVN Arvinas Inc
1,130
$33.90
$1.35
(3.83%)
| Watchers | 1,130 |
| 52-Wk Low | $13.57 |
| 52-Wk High | $53.08 |
| Market Cap | $2.32B |
| Volume | 409,421.00 |
| 52-Wk High | $53.08 |
| 52-Wk Low | $13.57 |
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up ResponsePR Newswire • 30 days ago
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response PR Newswire...
Share to Feed
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options...
Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 7,920,000...
Arvinas, Inc. (NASDAQ:ARVN Get Free Report)s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $42.60, but opened at $41.23. Arvinas...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...
This indicator may be signaling that ARVN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This indicator may be signaling ARVN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
This indicator may be signaling that ARVN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Schonfeld Strategic Advisors LLC reduced its position in shares of Arvinas, Inc. (NASDAQ:ARVN Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the...